share_log

3-Year VenoValve First-In-Human Data Presented At 49th Annual VEITH Symposium On Vascular And Endovascular Issues

3-Year VenoValve First-In-Human Data Presented At 49th Annual VEITH Symposium On Vascular And Endovascular Issues

在第49屆VEITH血管和血管內問題年度研討會上公佈了爲期3年的VenoValve人類首次數據
Benzinga Real-time News ·  2022/11/17 12:04
First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery No venous ulcer recurrences or CVI relapses Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)
首次在人體的VenoValve接受者平均在手術後3年內繼續受益於VenoValve 無靜脈潰瘍復發或 CVI 復發 所有研究終點改善的穩定性,包括反流、疾病嚴重程度 (rvCS) 和疼痛 (VAS)
IRVINE, CA / ACCESSWIRE / November 17, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Principal Investigator Dr. Jorge Hernando Ulloa presented positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve first-in-human clinical trial.
加利福尼亞州爾灣/Accesswire/2022 年 11 月 17 日/ 制定靜脈疾病治療新護理標準的公司EnvVeno Medical Corporation(納斯達克股票代碼:NVNO)(“EnvVeno” 或 “公司”)今天宣佈,首席研究員豪爾赫·埃爾南多·烏洛亞博士提供了參與先前結束的VenoValve首次人體臨床試驗的一組患者的三年期積極觀察數據。
The data...
在紐...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論